Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.52 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615017 | 1.00 | GRIA1 (0.52) | GRIA1GRIA4GRIK5GRIA3SLC7A5 | |
| SCHEMBL14485771 | 1.00 | GRIA1 (0.52) | GRIA1GRIA4GRIK5GRIA3SLC7A5 | |
| SCHEMBL6255381 | 0.95 | GRIA1 (0.48) | GRIA1GRIA4GRIK5GRIA3SLC7A5 | |
| SCHEMBL4757741 | 0.95 | GRIA1 (0.48) | GRIA1GRIA4GRIK5GRIA3SLC7A5 | |
| SCHEMBL5298700 | 0.93 | GRIA1 (0.47) | GRIA1GRIA4GRIK5GRIA3SLC7A5 | |
| Benzoquinone SCHEMBL23630290 | 0.87 | GRIA1 (0.46) | GRIA1GRIA4GRIK5GRIA3SLC7A5 | |
| SCHEMBL612974 | 0.85 | GRIA1 (0.43) | GRIA1GRIA4GRIK5GRIA3 | |
| SCHEMBL4407653 | 0.82 | GRIA1 (0.44) | GRIA1GRIA4GRIK5GRIA3ALDH1A1 | |
| SCHEMBL7954116 | 0.79 | ALDH1A1 (0.38) | GRIA1GRIA4GRIK5GRIA3ALDH1A1 | |
| SCHEMBL7954123 | 0.79 | ALDH1A1 (0.38) | GRIA1GRIA4GRIK5GRIA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4407952-A | OF GENETICALLY ENGINEERED ESCHERICHIA | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-10-04 | — | — | US | claimed |
| CN-118879592-A | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-11-01 | — | — | CN | disclosed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-4366777-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-25 | — | — | US | disclosed |
| WO-2024083220-A1 | LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE | 上海京新生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006114478-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2006-11-02 | — | — | WO | disclosed |
| EP-1134283-B1 | Method for producing L-Phenylalanine | AJINOMOTO KK (JP) | 2005-09-14 | — | — | EP | disclosed |
| US-6350596-B2 | Method for producing L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2002-02-26 | — | — | US | disclosed |
| US-20010044139-A1 | Method for producing L-phenylalanine | AJINOMOTO CO., INC. (JP) | 2001-11-22 | — | — | US | disclosed |
| EP-1134283-A1 | Method for producing L-Phenylalanine | Ajinomoto Co., Inc. (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-0138526-B1 | METHOD OF PRODUCING L-PHENYLALANINE BY FERMENTATION, AND BACTERIA THEREFOR | AJINOMOTO CO., INC. (JP) | 1989-04-26 | — | — | EP | disclosed |
| US-4407952-A | OF GENETICALLY ENGINEERED ESCHERICHIA | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-10-04 | — | — | US | disclosed |
| US-4403033-A | Method for producing L-phenylalanine by fermentation | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131032-A1 | AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS | GSTK1, GSTA2, GSTA1 | GRIA1 3540/4885GRIA4 3916/4885GRIK5 4204/4885 |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | GRIA1 1727/4885GRIA4 1378/4885GRIK5 1374/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | GRIA1 1727/4885GRIA4 1378/4885GRIK5 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.